As these innovations mature and the industry moves toward faster, more scalable GLP-1 production methods, manufacturers will unlock stronger business outcomes and patients will gain better access to the therapies they rely on
Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026
PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that directly influence how your body responds to GLP-1 therapy
The REWIND cardiovascular outcome trial also revealed that dulaglutide administration resulted in inferior ocular outcomes, leading to an increased need for interventions such as photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, or vitrectomy compared to placebo recipients [38]
[4] Fasting blood glucose and random glucose measurements provide additional information about day-to-day glycemic control
Both drugs support 510% weight loss with diet and exercise, but their safety profiles differ